Biopharma has promised $290B+ in US manufacturing in the past six monthsnews2025-08-21T17:02:22+00:00August 21st, 2025|Endpoints News|
Maven Clinic launches cycle tracking and male fertility testingnews2025-08-21T17:00:36+00:00August 21st, 2025|Endpoints News|
FDA approves Ionis’ RNA-targeting therapy to treat rare disease that causes swelling attacksnews2025-08-21T16:58:21+00:00August 21st, 2025|Endpoints News|
Trump’s ‘most favored nation’ policy will apply to EU generics news2025-08-21T16:08:20+00:00August 21st, 2025|Endpoints News|
Gilead joins the in vivo cell therapy race with $350M buyout of Interiusnews2025-08-21T15:31:42+00:00August 21st, 2025|Endpoints News|
Nicox eyes FDA submission as ocular hypertension drug passes Phase 3news2025-08-21T15:18:46+00:00August 21st, 2025|Endpoints News|
Sarepta refinances its debt; FDA delays decisions on Eylea HDnews2025-08-21T14:36:05+00:00August 21st, 2025|Endpoints News|
Dynavax says its shingles shot was ‘comparable’ to Shingrix in early readoutnews2025-08-21T12:00:17+00:00August 21st, 2025|Endpoints News|
Prader-Willi syndrome is not a zero-sum game. There’s room for many winnersnews2025-08-21T11:00:48+00:00August 21st, 2025|Endpoints News|
HHS staffers blame RFK Jr. for ‘deliberate destruction’ of trustnews2025-08-20T19:14:24+00:00August 20th, 2025|Endpoints News|
